Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TQB2102 versus TCbHP as neoadjuvant treatment for HER2-positive breast cancer
CTR20252440Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2102 in breast cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Sep 2025; status: active.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20252440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252440.